Alterity Therapeutics talks to Finance News Network
Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug
Read More
We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, PBT434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Alterity Therapeutics’ Finance News Network Presentation
On June 6 2019, Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, participated in the Finance News Network Inv
Read MoreAlterity Therapeutics Presents to Finance News Network
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – June 4, 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or
Read MoreReceive news from Alterity Therapeutics
